4-methyl-3-nitro-1H-pyridin-2-one | CAS:21901-18-8

We serve 4-methyl-3-nitro-1H-pyridin-2-one CAS:21901-18-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-methyl-3-nitro-1H-pyridin-2-one

Chemical Name:4-methyl-3-nitro-1H-pyridin-2-one
CAS.NO:21901-18-8
Synonyms:4-methyl-3-nitro-1H-pyridin-2-one
2-Hydroxy-4-methyl-3-nitropyridine
4-Methyl-3-nitro-2-pyridone
4-Methyl-3-nitro-2-pyridinol
2-Hydroxy-3-nitro-4-methylpyridine
2-Hydroxy-3-nitro-4-methyl-pyridin
Molecular Formula:C6H6N2O3
Molecular Weight:154.12300
 
Physical and Chemical Properties:
Density:1.36
Melting point:229-232ºC
Boiling point:352.5ºC
Flash point:167ºC
Index of Refraction:1.608
 
Specification:
Appearance:Off-white to pale yellow crystalline powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-methyl-3-nitro-1H-pyridin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Hydroxy-3-nitro-4-methyl-pyridin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydroxy-3-nitro-4-methylpyridine Use and application,2-Hydroxy-3-nitro-4-methylpyridine technical grade,usp/ep/jp grade.


Related News: Bulk bulk medicines: overcapacity, low prices, future capacity and output will be reduced, and it is possible to transfer foreign production.2-Amino-4,6-Dimethoxy-1,3,5-Triazine manufacturer This is how an API becomes a medicine.4-(Difluoromethoxy)benzenesulfonamide supplier It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.(S)-(+)-2,2-Dimethylcyclopropane Carboxamide vendor With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.